The prospectus of pelt medical was "invalid" for the second time in the Hong Kong stock exchange, and the listing plan was substantially delayed

2022 year 6 month 30 Japan , Bedouin finance and economics disclosed from the Hong Kong stock exchange that it is easy to understand , Beijing pelt Medical Technology Co., Ltd （ Hereinafter referred to as “ Pelt Medical ”） The prospectus of “ invalid ”. in fact , This is the second time that pelt medical has applied for listing “ invalid ”.

Before that , Pelt medical once 2021 year 6 month 29 The application materials for listing shall be submitted to the Hong Kong Stock Exchange on the th . however , Due to failure to 6 Hearing and offering within months , The launch status of pelt medical was 2021 year 12 month 29 Daily Automatic “ invalid ”, Same year 12 month 31 Daily redelivery table .

but “ invalid ” Not equal to failure . According to BeiDuo finance and Economics , Prospectus “ invalid ” It is the normal mechanism of HKEx , It can be understood as the company to be listed （ The issuer ） The financial audit data is out of date , It is necessary to supplement the financial data of the new period . According to the regulation , The issuer is “ invalid ” After 3 The latest financial information shall be supplemented within months , Then you can continue the listing process .

It is worth mentioning that , Pelt medical has been in the national small and medium-sized enterprise share transfer system （ namely “ The new three board ”） listed , Ticker “835879”, On 2019 Year end listing . period , Pelt medical has also twice prepared to be listed on the growth enterprise market of Shenzhen Stock Exchange , But they all declared “ abortion ”, He also planned to sprint to the scientific innovation board of Shanghai Stock Exchange , But it didn't make it .

According to the prospectus , Pelt medical is a provider of intelligent minimally invasive surgical solutions , The main business includes design 、 Development 、 Manufacture and sale of surgical instruments （ Focus on surgical staplers ）, And provide customized surgical training services . among , Surgical instruments are mainly surgical staplers .

As of the last practicable date , Pelt medical owns in China 248 Item patent （ Include 94 Invention patents ）, Owned in Europe 2 Item patent , Owned in the United States 5 Item patent , Owned in Japan 1 Item patent . As of the same date , Pelt medical has 62 Patent applications are pending .

And according to smart bud data , As of the latest, Pelt medical has 421 Patent application information , Among them, invention patents 182 Pieces of , Proportion 43.23%. Through algorithm analysis , Patent layout of pelt medical mainly focuses on stapler 、 Stapler 、 Counter nail seat 、 Linear cutting 、 Purse tongs and other technical fields .

performance , Pelt Medical 2018 year 、2019 Years and 2020 The annual revenue is 2.29 One hundred million yuan 、3.02 Million dollars 3.08 One hundred million yuan , Maintain an overall growth trend ; Profit for the year （ Net profit ） Respectively 3162.3 Ten thousand yuan 、4175.9 Million and $ 3435.8 Ten thousand yuan , among 2020 Year on year decrease 17.7%.

2021 Years ago 9 Months （ The first three quarters ）, Pelt medical's revenue is 2.49 One hundred million yuan ,2020 The revenue for the same period of the year was 2.20 One hundred million yuan ; Loss during the period （ A net loss ） by 293.5 Ten thousand yuan ,2020 The profit for the period in the same period of the year was 2585.8 Ten thousand yuan , From profit to loss .

In particular , The International Department of China Securities Regulatory Commission once worked in 2021 In the middle of, he gave feedback on the overseas listing application of pelt medical , It mainly focuses on the ownership structure, especially whether the actual controller will change due to listing , And the specific situation of the ESOP platform .

Besides , The International Department of China Securities Regulatory Commission asked pelter medical to explain the impact of the litigation on the existence of the employee stock ownership platform and the criminal filing of the actual controller of Fuhai Minxiang, the executive partner of Ningbo Xinquan, on the determination of the number of shareholders , And ask a lawyer to check and give legal opinions . Up to now , Pelt medical has not obtained the reply letter from the CSRC .

According to pelt medical prospectus , In the equity structure before this listing , The controlling shareholder of the company is Liuqing 、 Quchao couple , The two hold shares in total 41.42%, The founder of pelt Medical 、 Liu Qing, general manager and executive director, holds shares 27.80%, founder 、 Qu Chao, chairman of the board and executive director, holds shares 13.62%, Cadbury, an employee stock ownership platform, holds shares 4.81%.

meanwhile , Softbank China fund holds 11.15%, Cambridge Investment Holdings 10.0%, Weilun Investment Holdings 5.77%, Beijing Binghong holds shares of 2.88%. Besides , Shanghai Yonghua investment management 、 Dongfang Fuhai Investment Co., Ltd 、 Beijing Zhongfu Investment Co., Ltd. holds the shares of pelt medical .

It is also understood that , Pelt medical used to 2019 Annual cause “ No special operation personnel files have been established ” And was warned by Beijing Changping District Emergency Management Bureau , And impose a fine of RMB nine thousand nine hundred , The punishment decision document number is “（ Chang ） Emergency penalty 【2019】046 Number ”.